EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Leveraging COVID-era innovation for cervical cancer screening: Clinician awareness and attitudes toward self-sampling and rapid testing for HPV detection

Natalia M Rodriguez iD, Luke P Brennan iD, Layla Claure, Lara N Balian, Victoria L Champion iD, Michele R Forman

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0282853 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Natalia M Rodriguez und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health, College of Health and Human Sciences, Purdue University, West Lafayette, Indiana, United States of America. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Papillomavirus Infections, COVID-19. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cervical cancer screening rates are declining in the US, with persistent disparities among vulnerable populations. Strategies to better reach under-screened communities are needed. The COVID pandemic sparked major shifts in healthcare delivery, including the accelerated development and adoption of rapid diagnostic testing, broadened access to remote care, and growing consumer demand for self-testing, which could be leveraged for cervical cancer. Rapid tests for the detection of Human Papillomavirus (HPV) have the potential to improve cervical cancer screening coverage, and if coupled with patient-collected cervicovaginal samples, create an opportunity for self-testing. The objectives of this study were: 1) to examine whether COVID influenced clinician perspectives of rapid testing as a screening modality; and 2) to assess clinician awareness, perceived benefits and limitations, and willingness to adopt point-of-care HPV testing, patient self-sampling, and rapid HPV self-testing with self-collected samples. The methodology adopted consisted of an online cross-sectional survey (n = 224) and in-depth interviews (n = 20) were conducted with clinicians who perform cervical cancer screening in Indiana, ranked in the top ten states for cervical cancer mortality and with marked disparities across socio-demographic groups. The main findings show that about half the clinicians reported that the COVID pandemic had influenced their views on rapid testing as a screening modality both positively (greater public acceptability of rapid testing and impact on patient care) and negatively (concerns regarding accuracy of rapid tests). The majority of clinicians (82%) were willing to adopt rapid HPV testing at the point-of-care, while only 48% were willing to adopt rapid HPV self-testing with self-collected samples. In-depth interviews revealed provider concerns around patients’ ability to collect their own sample, report results correctly, and return to the clinic for follow-up and other preventive care. Addressing clinician concerns about self-sampling and rapid HPV testing, such as ensuring that rapid tests include sample adequacy controls, is necessary to mitigate barriers to adoption for cervical cancer screening.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsPapillomavirus InfectionsCOVID-19FemaleHumansHuman Papillomavirus VirusesVaginal SmearsEarly Detection of CancerCross-Sectional StudiesPapillomaviridaeSpecimen HandlingMass ScreeningSelf CarePatient Acceptance of Health Care

Autor:innen und Institutionen

  • Department of Public Health, College of Health and Human Sciences, Purdue University, West Lafayette, Indiana, United States of America.
  • Weldon School of Biomedical Engineering, College of Engineering, Purdue University, West Lafayette, Indiana, United States of America.
  • Indiana University Simon Comprehensive Cancer Center, Cancer Prevention and Control Program, Indianapolis, Indiana, United States of America.
  • Formerly at Department of Nutrition Science, College of Health and Human Sciences, Purdue University, West Lafayette, Indiana, United States of America.

ORCID-Profile: Natalia M Rodriguez, Luke P Brennan, Victoria L Champion

Förderung

  • NCI NIH HHS
  • NIGMS NIH HHS
  • National Cancer Institute

Zitieren

APA

Rodriguez, N. M., Brennan, L. P., Claure, L., Balian, L. N., Champion, V. L., & Forman, M. R. (2023). Leveraging COVID-era innovation for cervical cancer screening: Clinician awareness and attitudes toward self-sampling and rapid testing for HPV detection. PLOS ONE. https://doi.org/10.1371/journal.pone.0282853

Vancouver

Rodriguez NM, Brennan LP, Claure L, Balian LN, Champion VL, Forman MR. Leveraging COVID-era innovation for cervical cancer screening: Clinician awareness and attitudes toward self-sampling and rapid testing for HPV detection. PLOS ONE. 2023. doi:10.1371/journal.pone.0282853

BibTeX
@article{Rodriguez2023,
  author = {Rodriguez, Natalia M and Brennan, Luke P and Claure, Layla and Balian, Lara N and Champion, Victoria L and Forman, Michele R},
  title = {Leveraging COVID-era innovation for cervical cancer screening: Clinician awareness and attitudes toward self-sampling and rapid testing for HPV detection},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0282853}
}
Kostenlos starten →